JP2009537532A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2009537532A5 JP2009537532A5 JP2009511024A JP2009511024A JP2009537532A5 JP 2009537532 A5 JP2009537532 A5 JP 2009537532A5 JP 2009511024 A JP2009511024 A JP 2009511024A JP 2009511024 A JP2009511024 A JP 2009511024A JP 2009537532 A5 JP2009537532 A5 JP 2009537532A5
- Authority
- JP
- Japan
- Prior art keywords
- alkyl
- hydrogen
- compound
- independently selected
- bromine
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US74722006P | 2006-05-15 | 2006-05-15 | |
| US84996806P | 2006-10-06 | 2006-10-06 | |
| PCT/US2007/011622 WO2007133772A2 (en) | 2006-05-15 | 2007-05-15 | Cdki pathway inhibitors as selective inhibitors of tumor cell growth |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2009537532A JP2009537532A (ja) | 2009-10-29 |
| JP2009537532A5 true JP2009537532A5 (enExample) | 2012-09-20 |
Family
ID=38694543
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2009511024A Pending JP2009537532A (ja) | 2006-05-15 | 2007-05-15 | 腫瘍細胞増殖の選択的阻害剤としてのｃｄｋｉ経路阻害剤 |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US20080200531A1 (enExample) |
| EP (1) | EP2023925A4 (enExample) |
| JP (1) | JP2009537532A (enExample) |
| AU (1) | AU2007249761A1 (enExample) |
| CA (1) | CA2652339A1 (enExample) |
| WO (1) | WO2007133772A2 (enExample) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2011289407B2 (en) | 2010-08-11 | 2015-06-18 | Philadelphia Health & Education Corporation | Novel D3 dopamine receptor agonists to treat dyskinesia in Parkinson's disease |
| CA2853729A1 (en) * | 2011-10-28 | 2013-05-02 | Board Of Regents, The University Of Texas System | Novel compositions and methods for treating cancer |
| CN103468786B (zh) * | 2012-06-06 | 2017-06-13 | 上海吉凯基因化学技术有限公司 | 人cdkl3基因的用途及其相关药物 |
| WO2014089450A1 (en) | 2012-12-06 | 2014-06-12 | Senex Biotechnology, Inc. | Specific inhibitors of cdk3 |
| US10584369B2 (en) * | 2013-01-11 | 2020-03-10 | Senex Biotechnology, Inc. | Cell-based methods for measuring activity of a protein inhibitor |
| JP6607852B2 (ja) | 2013-10-28 | 2019-11-20 | ドレクセル ユニバーシティ | 注意障害用および認知障害用ならびに神経変性障害に関連する認知症用の治療剤 |
| JP7152784B2 (ja) | 2017-04-03 | 2022-10-13 | 京都薬品工業株式会社 | 新規サイクリン依存性キナーゼ８及び／又は１９阻害剤 |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3915990A (en) * | 1973-03-13 | 1975-10-28 | Nelson Res & Dev | Tryptamines |
| US5849733A (en) * | 1996-05-10 | 1998-12-15 | Bristol-Myers Squibb Co. | 2-thio or 2-oxo flavopiridol analogs |
| DE69912808T2 (de) * | 1999-12-08 | 2004-09-30 | Centre National De La Recherche Scientifique (C.N.R.S.) | Verwendung von Hymenialdisin und dessen Derivaten zur Herstellung therapeutischer Mittel |
| CA2539000A1 (en) * | 2003-09-18 | 2005-03-24 | Novartis Ag | Combination of a histone deacetylase inhibitor with a death receptor ligand |
| CA2611896A1 (en) * | 2005-05-18 | 2006-11-23 | Forschungsverbund Berlin E.V. | Non-peptidic inhibitors of akap/pka interaction |
-
2007
- 2007-05-15 AU AU2007249761A patent/AU2007249761A1/en not_active Abandoned
- 2007-05-15 US US11/803,739 patent/US20080200531A1/en not_active Abandoned
- 2007-05-15 WO PCT/US2007/011622 patent/WO2007133772A2/en not_active Ceased
- 2007-05-15 EP EP07809083A patent/EP2023925A4/en not_active Withdrawn
- 2007-05-15 JP JP2009511024A patent/JP2009537532A/ja active Pending
- 2007-05-15 CA CA002652339A patent/CA2652339A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2009537532A5 (enExample) | ||
| JP2010526814A5 (enExample) | ||
| JP2010506942A5 (enExample) | ||
| JP2018535967A5 (enExample) | ||
| JP2008535903A5 (enExample) | ||
| JP2009502743A5 (enExample) | ||
| JP2010511721A5 (enExample) | ||
| JP2009515988A5 (enExample) | ||
| NZ702914A (en) | Ite for cancer intervention and eradication | |
| JP2011518833A5 (enExample) | ||
| JP2010502730A5 (enExample) | ||
| NZ610104A (en) | Polymorphic forms of 2-(5-bromo-4-(4-cyclopropylnaphthalen-1-yl)-4h-1,2,4-triazol-3-ylthio) acetic acid and uses thereof | |
| JP2007302689A5 (enExample) | ||
| JP2009531376A5 (enExample) | ||
| RU2009115179A (ru) | Кристаллические формы соединения тиазолидиндиона и способ его получения | |
| JP2015512943A5 (enExample) | ||
| JP2014510149A5 (enExample) | ||
| JP2011527666A5 (enExample) | ||
| JP2017526662A5 (enExample) | ||
| JP2012508274A5 (enExample) | ||
| BRPI0506765A (pt) | composto ou um seu sal, hidrato e/ou pró-droga farmaceuticamente aceitáveis, composição farmacêutica, métodos para inibir a produção de beta-amilóide em um paciente e para tratar de uma doença, kit farmacêutico, uso de um composto ou de uma composição | |
| JP2013500342A5 (enExample) | ||
| JP2010527985A5 (enExample) | ||
| JP2006501201A5 (enExample) | ||
| TNSN08020A1 (en) | 1,4-dihydropyridine-fused heterocycles, process for preparing the same, use and compositions containing them |